PMC:6323553 / 34566-35329 JSONTXT

{"target":"https://pubannotation.org/docs/sourcedb/PMC/sourceid/6323553","sourcedb":"PMC","sourceid":"6323553","source_url":"https://www.ncbi.nlm.nih.gov/pmc/6323553","text":"The PRS has the potential to improve stratification for screening, while ER-specific PRSs may be informative for prevention with endocrine therapies. Previous studies have suggested that the earlier PRS77 was more predictive for screen-detected breast cancers than interval cancers, and that breast cancers arising among women with a low PRS are more aggressive compared with those arising in women with a high PRS, perhaps reflecting the stronger associations with ER-positive disease.31, 32 It will therefore be important to evaluate carefully the associations between the new PRS313 and other tumor characteristics. Clinical translational studies are required to assess the risks and benefits of including the PRS in the context of current screening protocols.","tracks":[{"project":"2_test","denotations":[{"id":"30554720-26628467-2052427","span":{"begin":486,"end":488},"obj":"26628467"},{"id":"30554720-25488685-2052428","span":{"begin":490,"end":492},"obj":"25488685"}],"attributes":[{"subj":"30554720-26628467-2052427","pred":"source","obj":"2_test"},{"subj":"30554720-25488685-2052428","pred":"source","obj":"2_test"}]}],"config":{"attribute types":[{"pred":"source","value type":"selection","values":[{"id":"2_test","color":"#ecc393","default":true}]}]}}